Targeting T-cell Malignancies with CAR-based Immunotherapy - Challenges and Potential Solutions

Attend a keynote webinar exploring the complex challenges and innovative solutions in developing CAR-based immunotherapy for T-cell malignancies. Learn from Dr. Sunil S. Raikar, Assistant Professor at Emory University School of Medicine and Physician-Scientist specializing in cellular immunotherapy, as he examines why CAR T-cell therapy has achieved remarkable success in treating B-cell malignancies but faces significant obstacles when applied to T-cell cancers. Discover the three primary challenges hindering progress: CAR T-cell fratricide due to shared antigen expression between normal and malignant T cells, life-threatening immunosuppression from off-tumor toxicity, and product contamination risks when isolating T cells from patients with T-cell malignancies. Explore various preclinical and clinical approaches being tested to overcome these barriers, including disrupting target antigen expression on CAR-modified T cells, targeting antigens with limited T-cell expression, and utilizing third-party donor cells that are either non-alloreactive or genome-edited at the TRAC locus. Examine the current landscape of CAR-based strategies targeting T-cell antigens and evaluate emerging therapeutic approaches that could successfully translate this innovative immunotherapy for T-cell diseases. Participate in a live Q&A session to deepen understanding of this cutting-edge field and earn PACE credits upon completion.